SG3 Management’s AnaptysBio ANAB Stock Holding History

SG3 Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,000	Closed	-$216K	–	1004
2021 Q1	$216K	Buy	+10,000	New	+$252K	0.01%	949

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SG3 Management's ANAB Position: Q2 2021 in Review

SG3 Management sold out of AnaptysBio (ANAB) in Q2 2021, closing a stake of 10,000 shares — an estimated $216K sold.

SG3 Management first reported a position in ANAB in Q1 2021 and held it in 1 quarter. The position peaked at $216K in Q1 2021. 122 funds tracked by Wall St. Rank hold ANAB as of Q2 2021.

SG3 Management reported no remaining AnaptysBio position as of Q2 2021 after selling out during the quarter.
SG3 Management sold 10,000 AnaptysBio shares in Q2 2021, an estimated $216K.
SG3 Management first reported a position in AnaptysBio in Q1 2021 and held it in 1 quarter.
SG3 Management's AnaptysBio position peaked at $216K in Q1 2021.
122 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2021.

Based on SG3 Management's 13F filing for Q2 2021, filed 16 Aug 2021.